Argyriou, A.A.; Dermitzakis, E.V.; Chondrogianni, M.; Foska, A.; Rikos, D.; Soldatos, P.; Vikelis, M., on behalf of the Greek Research Alliance for the Study of Headache and Pain (GRASP) Study Group.
Testing the Efficacy of Eptinezumab 100 mg in the Early Prevention of Chronic Migraine over Weeks 1 to 4: Prospective Real-World Data from the GRASP Study Group. J. Clin. Med. 2025, 14, 8793.
https://doi.org/10.3390/jcm14248793
AMA Style
Argyriou AA, Dermitzakis EV, Chondrogianni M, Foska A, Rikos D, Soldatos P, Vikelis M on behalf of the Greek Research Alliance for the Study of Headache and Pain (GRASP) Study Group.
Testing the Efficacy of Eptinezumab 100 mg in the Early Prevention of Chronic Migraine over Weeks 1 to 4: Prospective Real-World Data from the GRASP Study Group. Journal of Clinical Medicine. 2025; 14(24):8793.
https://doi.org/10.3390/jcm14248793
Chicago/Turabian Style
Argyriou, Andreas A., Emmanouil V. Dermitzakis, Maria Chondrogianni, Aikaterini Foska, Dimitrios Rikos, Panagiotis Soldatos, and Michail Vikelis on behalf of the Greek Research Alliance for the Study of Headache and Pain (GRASP) Study Group.
2025. "Testing the Efficacy of Eptinezumab 100 mg in the Early Prevention of Chronic Migraine over Weeks 1 to 4: Prospective Real-World Data from the GRASP Study Group" Journal of Clinical Medicine 14, no. 24: 8793.
https://doi.org/10.3390/jcm14248793
APA Style
Argyriou, A. A., Dermitzakis, E. V., Chondrogianni, M., Foska, A., Rikos, D., Soldatos, P., & Vikelis, M., on behalf of the Greek Research Alliance for the Study of Headache and Pain (GRASP) Study Group.
(2025). Testing the Efficacy of Eptinezumab 100 mg in the Early Prevention of Chronic Migraine over Weeks 1 to 4: Prospective Real-World Data from the GRASP Study Group. Journal of Clinical Medicine, 14(24), 8793.
https://doi.org/10.3390/jcm14248793
